title: Low IL10 serum levels as key factor for predicting the sustained virological response to IFNα/ribavirin in Brazilian patients with HCV carrying IL28B CT/TT genotype.
abstract: METHODS
  IL28B polymorphisms rs12979860 CC genotype was associated to protection of HCV infection and sustained virological response (SVR) in HCV infected patients treated with pegIFNα/ribavirin (IFNα/RIB), however, this polymorphism frequency varies depending on genetic components. Studies with larger number of Brazilian individuals, determining IL28B polymorphisms is lacking. Regarding to treatment response, the levels of IL10 seem to influence response to IFNα/RIB therapy. Thus, the IL28B polymorphism frequency was investigated in health controls and infected HCV patients, as well as, in patients who reach SVR vs Non-SVR. Also, to gain insight into the interplay between IL28B genotypes, IL10 levels and therapy response, a subgroup of genotyped HCV patients SVR and Non-SVR were analyzed regarding the IL10 production.
  
  
  METHODS
  It was enrolled 487 HCV infected patients and 234 healthy individuals. Patients with response to IFNα/RIB were classified as SVR (n = 81) and Non-SVR (n = 123). TAQMAN probes were used for genotyping the SNP rs12979860, resulting in CC, CT or TT genotypes. In one hundred one patients, the levels IL10 were measured at week 4 of IFNα/RIB.
  
  
  RESULTS
  CC genotype was associated to SVR (p = 0.029) and its frequency was higher in healthy individuals vs patients (p = 0.02). Patients carrying CT/TT with IL10<10 pg/mL, had a chance of 2.72 to achieve SVR in multivariate model (p = 0.043).
  
  
  CONCLUSIONS
  CC genotype was associated to SVR and protection to HCV infection. Moreover, IL28B genotyping and IL10 serum levels could be further explored as a useful algorithm for identify the CT/TT SVR patients.
authors.affiliation: Liver Institute of Pernambuco, Recife, PE 50100-130, Brazil; Post-Graduate Program-RENORBIO, UECE, Fortaleza, CE 60714-903, Brazil.
authors.forename: Luydson Richardson Silva
authors.initials: LR
authors.lastname: Vasconcelos
authors.affiliation: University of Pernambuco, Recife, PE 50100-130, Brazil.
authors.forename: Patricia
authors.initials: P
authors.lastname: Moura
authors.affiliation: Post-Graduate Program-RENORBIO, UECE, Fortaleza, CE 60714-903, Brazil; Federal University of São Francisco Valley, Petrolina, PE 56304-917, Brazil.
authors.forename: Rodrigo Feliciano
authors.initials: RF
authors.lastname: do Carmo
authors.affiliation: Liver Institute of Pernambuco, Recife, PE 50100-130, Brazil.
authors.forename: Luciano Beltrão
authors.initials: LB
authors.lastname: Pereira
authors.affiliation: Post-Graduate Program-RENORBIO, UECE, Fortaleza, CE 60714-903, Brazil; University of Pernambuco, Recife, PE 50100-130, Brazil.
authors.forename: Maria do Socorro de Mendonça
authors.initials: Mdo S
authors.lastname: Cavalcanti
authors.affiliation: Liver Institute of Pernambuco, Recife, PE 50100-130, Brazil; University of Pernambuco, Recife, PE 50100-130, Brazil.
authors.forename: Dayse Celia Barbosa Lins
authors.initials: DC
authors.lastname: Aroucha
authors.affiliation: Federal University of Pernambuco, Recife, PE 50100-130, Brazil.
authors.forename: Rosa Amália
authors.initials: RA
authors.lastname: Dutra
authors.affiliation: Liver Institute of Pernambuco, Recife, PE 50100-130, Brazil; University of Pernambuco, Recife, PE 50100-130, Brazil.
authors.forename: Leila Maria Moreira Beltrão
authors.initials: LM
authors.lastname: Pereira
mesh_terms: D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D015870:Gene Expression; D005838:Genotype; D016174:Hepacivirus / Q000187:drug effects / Q000276:immunology; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000235:genetics* / Q000276:immunology / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D007372:Interferons; D016753:Interleukin-10 / Q000097:blood / Q000235:genetics* / Q000276:immunology; D007378:Interleukins / Q000235:genetics* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011110:Polymorphism, Genetic; D011379:Prognosis; D011994:Recombinant Proteins / Q000627:therapeutic use; D012254:Ribavirin / Q000627:therapeutic use; D019562:Viral Load / Q000187:drug effects; D000095022:Interferon Lambda
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007372:Interferons; D016753:Interleukin-10; D007378:Interleukins; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012254:Ribavirin; C000624353:interferon-lambda, human; D000095022:Interferon Lambda; C508609:IL10 protein, human; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a
keywords: HCV; IL10; IL28b; Polymorphism; Therapy